Organogenesis/$ORGO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Organogenesis
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
Ticker
$ORGO
Sector
Primary listing
Employees
854
Headquarters
Website
Organogenesis Metrics
BasicAdvanced
$311m
-
-$0.12
1.33
-
Price and volume
Market cap
$311m
Beta
1.33
52-week high
$7.08
52-week low
$2.04
Average daily volume
1.4m
Financial strength
Current ratio
3.532
Quick ratio
2.74
Long term debt to equity
16.032
Total debt to equity
18.582
Profitability
EBITDA (TTM)
36.004
Gross margin (TTM)
73.89%
Net profit margin (TTM)
0.53%
Operating margin (TTM)
3.25%
Effective tax rate (TTM)
36.47%
Revenue per employee (TTM)
$600,000
Management effectiveness
Return on assets (TTM)
2.12%
Return on equity (TTM)
0.73%
Valuation
Price to revenue (TTM)
0.598
Price to book
1.27
Price to tangible book (TTM)
1.47
Price to free cash flow (TTM)
18.008
Free cash flow yield (TTM)
5.55%
Free cash flow per share (TTM)
0.134
Growth
Revenue change (TTM)
12.19%
Earnings per share change (TTM)
-24.59%
3-year revenue growth (CAGR)
3.71%
3-year earnings per share growth (CAGR)
4.66%
What the Analysts think about Organogenesis
Analyst ratings (Buy, Hold, Sell) for Organogenesis stock.
Organogenesis Financial Performance
Revenues and expenses
Organogenesis Earnings Performance
Company profitability
Organogenesis News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs